On June+10, 5438, Shandong Changwei Central Medicinal Materials Company was established.
1964
On June+10, 5438, the name of the factory was changed to "Weifang Wholesale Station Processing Factory of China Medicinal Materials Company".
1978
& lt/strong & gt； Approved by the Shandong Provincial Health Department (78) Lu Weiyao Zi No.83, Xinkeshu tablets were officially put into production. 1980
June 5438+10, the name of the factory was changed to "Weifang Chinese Medicine Factory in Shandong Province".
In March, the "Shoushan" brand trademark was officially launched. 1990
In March, it passed the renewal and acceptance of pharmaceutical factory production license organized by Shandong Provincial Health Department.
199 1 year
On June+10, 5438, the name of the factory was changed from "Weifang Chinese Medicine Factory in Shandong Province" to "Weifang Chinese Medicine Factory in Shandong Province", and the affiliation remained unchanged.
165438+ 10 In October, Amber Xiaoshi Granules won the silver prize in the 40th Eureka World Invention Expo.
1992
On June+10, 5438, the factory was renamed as "Weifang Pharmaceutical Group Company Chinese Medicine Factory", which was under the leadership of Shandong Weifang Pharmaceutical Group Company.
1993
In May, Xinkeshu tablets entered the basic list of clinical drugs in hospitals nationwide.
165438+ 10, the name of the factory was changed to "Shandong Weifang Pharmaceutical Group Co., Ltd. Chinese Medicine Factory", which belongs to Shandong Weifang Pharmaceutical Group.
1994
In February, Xinkeshu tablets, Hupo Xiaoshi granules and Xiaoer antipyretic granules were listed as the second-class protected varieties of traditional Chinese medicine with a protection period of 7 years.
In March, Xinkeshu tablets were listed in Shanghai free medical care catalogue.
In July, it passed the acceptance of hygiene license and drug production license organized by Shandong Provincial Health Department.
1996
In February, Xinkeshu Tablet was recommended by state administration of traditional chinese medicine as "China Famous Brand Product of Traditional Chinese Medicine". 1997
In March, the development of Xinkeshu film-coated tablets won the second prize of scientific and technological progress of Shandong Provincial Administration of Medicine.
In May, Xinkeshu tablets were listed in the catalogue of public medical care in Beijing.
At the end of August, the expansion and reconstruction project of the new Keshu workshop was completed and passed the acceptance.
In June, 1 1, Xinkeshu film-coated tablets were included in the national key new product list and obtained the national key new product certificate.
1998
& lt/strong & gt； In April, Xinkeshu film-coated tablets won the national key new product certificate jointly issued by the State Science and Technology Commission, the State Taxation Bureau, the Ministry of Foreign Trade and Economic Cooperation, the State Bureau of Technical Supervision and the State Environmental Protection Bureau.
10 in June, approved by Weifang Municipal People's Government Office [1998] 120, it was designated as a medium-sized (I) enterprise. In 2000,
In February, the in vitro diagnostic reagent workshop passed the GMP certification organized by the State Administration of Medical Products.
In May, Xinkeshu tablets, the company's exclusive Chinese medicine protection variety, was listed in the national basic medical insurance and industrial injury insurance drug list.
In July, the State Administration of Pharmaceutical Products issued the first batch of over-the-counter drugs, and 34 varieties and 36 specifications of products were selected.
200 1 year
& lt/strong & gt； In June, 5438+10, the declared xinkeshu capsule obtained the second-class protection variety of traditional Chinese medicine, and the protection period was 7 years.
In February, 34 varieties and 35 specifications of over-the-counter drugs passed the examination and approval of the provincial US Food and Drug Administration and were certified.
In the same month, Xinkeshu tablets, Amber Xiaoshi granules and Xiaoer antipyretic granules were protected by the second phase of Chinese traditional medicine for 7 years.
In the same month, the "Helicobacter pylori urease diagnostic kit project" was listed as a national torch plan project by the Ministry of Science and Technology.
In April, the solid preparation workshop successfully passed the GMP certification on-site acceptance organized by the State Administration of Pharmaceutical Products.
In the same month, Hong Ju Pear Paste was awarded the second-class protection of national protected varieties of traditional Chinese medicine for 7 years.
In 2002
& lt/strong & gt； In February, the signing ceremony of the property right transfer contract between Shandong Weifang Pharmaceutical Group Co., Ltd. and Beijing Wohua Biotechnology Co., Ltd. was held in Weifang Hua Fu Hotel. Zhang Xinqi, Deputy Secretary of the Municipal Party Committee and Executive Vice Mayor, attended the signing ceremony and delivered a speech. Zhao Bingxian, Zhao Jun and Zhang Fazhong signed the contract on behalf of China Bio, Weiyao Group and the company's senior management respectively.
In February, the first meeting of the first board of directors of Weifang Wohua Pharmaceutical was held in Weifang. Zhao Bingxian was elected as the chairman, Zhao Jun as the president, Zhang Fazhong as the executive vice president, Zhang Ge as the chief financial officer and Huang Gang as the secretary of the board.
In February, with the approval of Weifang Administration for Industry and Commerce High-tech Industrial Development Zone Branch, Weifang Wohua Pharmaceutical Technology Co., Ltd. was incorporated and obtained a business license in 2002. The legal representative of the company is Zhao Bingxian, the person in charge is Zhao Jun, and the registered capital is16.35 million yuan.
In August, the Shoushan Xinkeshu Research Center of Weifang Wohua Pharmaceutical Technology Co., Ltd. was registered and established.
June165438+1October Weifang Economic and Trade Commission and Statistics Bureau approved the company as a medium-sized (II) enterprise.
In 2003
In March, Shandong Wohua Pharmaceutical Technology Co., Ltd. was established.
In the same month, antiviral oral liquid was listed as a second-class protected variety of traditional Chinese medicine, with a protection period of 7 years.
In April, the project of "Preparation of Xinkeshu Dripping Pills" declared by the company was included in the National "863 Plan" and won the innovation fund of this project.
65438+February, the company carried out GMP transformation of 9 dosage forms in the third workshop, and passed the certification at one time. So far, all the production dosage forms of the company have passed GMP certification.
In the same month, Kingdee software was officially used in production management, warehousing management and financial management to realize office modernization. In 2004
On June+10, 5438, the company implemented the issuance plan, and with the approval of the Shandong Provincial People's Government, the registered capital of the company increased from 39.99 million yuan to 5 1.99 million yuan.
In April, the company's "Xinkeshu Dripping Pill Reconstruction Project", "Xinkeshu Tablet Reconstruction Project", "Traditional Chinese Medicine Pieces and Granules Reconstruction Project" and "Biological Diagnostic Reagent Reconstruction Project" were included in the technical transformation directional plan of Shandong Province in 2004, with a total planned investment of 65.438+0.7 billion yuan.
In May, the company established leading groups for stock issuance and listing, price, medical insurance, bidding, quality, government relations, internal risk prevention and emergencies.
In the same month, the company was recognized by the Ministry of Science and Technology as "Key High-tech Enterprise of National Torch Program".
In June, Xinkeshu Dropping Pill Project was listed as "Technological Innovation Project for Small and Medium-sized Science and Technology Enterprises" by the Ministry of Science and Technology of China, and won the bid in one fell swoop in the "Research on Key Technologies of Innovative Drugs and Modernization of Traditional Chinese Medicine" organized by the Science and Technology Department of Shandong Province.
In August, after the acceptance by Shandong Securities Regulatory Bureau, the company successfully passed the listing counseling acceptance and was highly praised.
In the same month, the newly added dropping pills workshop passed the on-site acceptance by the provincial drug supervision department.
In September, Amber Xiaoshi Granules and Motherwort Oral Liquid were included in the newly adjusted national drug list of basic medical insurance and industrial injury insurance in 2005.
In April, the company successfully passed the listing counseling and acceptance organized by Shandong Securities Regulatory Bureau.
In the same month, our company's motherwort oral liquid obtained the national certificate of protection of traditional Chinese medicine and was listed as the second-class protected variety of traditional Chinese medicine, with a protection period of 7 years.
In July, the CIS system designed by Beijing Zhengbang Advertising Company was commissioned by the company to officially enter the import stage, and the new logo of Wohua and the slogan "People are good at medicine, doctors are good at people" were officially launched. The new logo is composed of blue and green, and the whole logo is a deformation of the word "wo", which has profound implications;
In September, the company's in vitro diagnostic reagent workshop successfully passed GMP re-certification.
In June165438+1October, the land use index of the new factory area of the company's development zone 150 mu was approved, and the planning of the new area was approved by the planning department of the development zone.
In 2006
On June+10, 5438, the solid preparation workshop successfully passed the second GMP certification on-site acceptance organized by the State Administration of Medical Supplies.
In April, the company's "High-tech Industrial Development Zone" construction project passed the process design demonstration of the US Food and Drug Administration, High-tech Zone and Weifang Fire Bureau in Shandong Province.
In May, the foundation stone laying ceremony of the company's new factory construction project was held in the High-tech Development Zone.
In June, the "Construction Project of Shandong Wohua Chinese Medicine Research Institute, a special fund for the development of high-tech industries in Weifang" passed the evaluation of Weifang Municipal Government.
In the same month, the company registered the Wohua trademark and gradually quoted it on the product packaging.
In September, Xinkeshu Tablets passed the expert review of "High-quality Chinese Patent Medicine with Good Price" organized by china association of traditional chinese medicine.
65438+February 18, the 78th meeting of the Audit Committee of the State Securities Regulatory Commission approved the company's application to issue A shares in Shenzhen Stock Exchange.
In 2007
On October 4th, 65438+65438/kloc-0, the company issued180,000 shares in Shenzhen Stock Exchange at the issue price of 10.85 yuan/share.
65438+10.24, the company's stock was officially listed on the SME board of Shenzhen Stock Exchange with the stock code 002 107. The success of stock listing consolidated and developed the company's core competitive advantage, enhanced the company's development potential, and the company entered a period of rapid development.
On June+10, 5438, the company's new drug Xinkeshu Dripping Pills passed the examination and approval of China National Intellectual Property Administration invention patent, becoming the first variety with national patent, with a patent period of 20 years.
In February, the National Development and Reform Commission issued the Notice of the National Development and Reform Commission on Setting the Maximum Retail Price of 278 Chinese Patent Medicines for Internal Medicine. The company's product Xinkeshu tablets (specification: 0.3g48 film-coated tablets) will have high quality and good price from March 15, and its highest retail price will be adjusted from 19.8 yuan/box to 24.2 yuan/box.
In April, the project "Development and Research of Five New Chinese Medicine Xinkeshu Dropping Pills" undertaken by the company passed the acceptance of Shandong Science and Technology Department.
In September, the company's leading product "Preparation of Xinkeshu Tablets" won the patent certificate issued by the State Patent Office with a patent term of 20 years.
165438+ 10, the company was recognized as a national high-tech enterprise again.
65438+February, the company's new drug Naoxueshu Oral Liquid passed the examination and approval, and obtained the production approval and new drug certificate issued by SFDA. The approval number was: National Medicine Zhunzi Z20070059.
In February 65438, Zhao Jun, the vice chairman of the company, was elected as the representative of the 15th Weifang Municipal People's Congress and a candidate for the Standing Committee of Weifang Municipal People's Congress.